Sign In
Buy ONCT
$0.527
+0 (+0%)
At Close: Feb 28, 2025
Oncternal Therapeutics Appoints Pablo Urbaneja as Sr. Vice President, Corporate Development
04:05pm, Thursday, 01'st Jul 2021
SAN DIEGO, July 01, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today annou
Oncternal Therapeutics: New Data Continues To Derisk
09:44am, Sunday, 20'th Jun 2021
Oncternal is a small biotech player with two major assets: Cirmtuzumab and TK216. Recent data updates have solidified Oncternal's approach in Mantle Cell Lymphoma and Ewing Sarcoma.
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 01'st Jun 2021
SAN DIEGO, June 01, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today annou
Oncternal Therapeutics (ONCT) Stock: Over 9% Increase Pre-Market Explanation
06:40am, Thursday, 20'th May 2021
The stock price of Oncternal Therapeutics Inc (NASDAQ: ONCT) increased by over 9% pre-market. This is why it happened.
SAN DIEGO, May 19, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announ
Oncternal Therapeutics Presents Updated Interim Data for Cirmtuzumab in Combination with Ibrutinib at ASCO 2021
05:01pm, Wednesday, 19'th May 2021
SAN DIEGO, May 19, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announ
Oncternal Therapeutics, Inc. (ONCT) CEO Jim Breitmeyer on Q1 2021 Results - Earnings Call Transcript
10:16pm, Thursday, 06'th May 2021
Oncternal Therapeutics, Inc. (ONCT) CEO Jim Breitmeyer on Q1 2021 Results - Earnings Call Transcript
Oncternal Therapeutics Announces Appointment of Chase Leavitt as General Counsel
04:41pm, Monday, 12'th Apr 2021
SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today anno
Oncternal Therapeutics Announces Presentation of Three Posters at AACR 2021 Virtual Meeting
07:00am, Monday, 12'th Apr 2021
SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today anno
Oncternal Therapeutics' (ONCT) Shares March Higher, Can It Continue?
06:03am, Friday, 09'th Apr 2021
As of late, it has definitely been a great time to be an investor in Oncternal Therapeutics, Inc. (ONCT).
Oncternal Therapeutics (ONCT) Soars 8.4%: Is Further Upside Left in the Stock?
05:18am, Thursday, 08'th Apr 2021
Oncternal Therapeutics (ONCT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the nea
Why Oncternal Therapeutics Stock Is Popping Today
03:52pm, Wednesday, 07'th Apr 2021
This analyst is excited about the company's prospects.
5 Stocks to Buy on New Analyst Coverage
09:06am, Wednesday, 07'th Apr 2021
Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Interactive Brokers (IBKR), Avid (CDMO), Oncternal (ONCT), Amtech (ASYS) and Aytu.
Implied Volatility Surging for Oncternal Therapeutics (ONCT) Stock Options
09:05am, Monday, 05'th Apr 2021
Investors need to pay close attention to Oncternal Therapeutics (ONCT) stock based on the movements in the options market lately.
Oncternal Therapeutics: Opportunistic Investment In A ROR-1 Biotech
02:45am, Thursday, 01'st Apr 2021
Oncternal Therapeutics: Opportunistic Investment In A ROR-1 Biotech
